Cullen/Frost Bankers, Inc. Castle Biosciences Inc Transaction History

Cullen/Frost Bankers, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.08 - $30.0 $1,265 - $2,100	-70 Reduced 2.54%	2,685 $63,000
Q2 2022 Aug 05, 2022	SELL	$16.0 - $45.99 $39,440 - $113,365	-2,465 Reduced 47.22%	2,755 $60,000
Q1 2022 May 09, 2022	SELL	$33.17 - $46.98 $6,965 - $9,865	-210 Reduced 3.87%	5,220 $234,000
Q4 2021 Feb 07, 2022	BUY	$39.06 - $67.58 $62,691 - $108,465	1,605 Added 41.96%	5,430 $233,000
Q3 2021 Nov 04, 2021	BUY	$60.13 - $77.6 $1,202 - $1,552	20 Added 0.53%	3,825 $254,000

Q1 2021 May 05, 2021	BUY	$58.92 - $97.33 $224,190 - $370,340	3,805 New	3,805 $260,000

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.